Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 17%
Buy 42%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is positioned positively due to the anticipated improvement in the overall response rate (ORR) for its combination therapy Zele with Keytruda, potentially rising to 55%, benefiting from favorable key opinion leader (KOL) feedback on its superiority over existing treatments like Padcev. Additionally, the company's product candidates, particularly BT5528, are expected to offer enhanced safety and tolerability compared to earlier-generation antibody-drug conjugates, which may lead to increased clinical efficacy and adoption. Furthermore, the rising investor interest in the company's innovative Bicycle design underscores the potential for expanded tumor targeting and improved safety profiles, particularly within the burgeoning radiopharmaceutical sector.

Bears say

Bicycle Therapeutics has faced significant stock pressure, with shares declining 45% year-to-date, primarily attributed to perceived weaknesses in its clinical data and increased competition in its oncology indications. Furthermore, uncertainties surrounding its product candidate Zelenectide's efficacy compared to market competitors like Padcev create potential risks, including a projected 25% downside if safety concerns arise. In addition, the company may face challenges from third-party IP issues and a shift in the development landscape towards next-generation macrocyclic peptides, which could negatively impact its competitive positioning and overall platform valuation.

BCYC has been analyzed by 12 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 42% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 12 analysts, BCYC has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.